Breaking News, Financial News

Financial Report: Johnson & Johnson

Johnson & Johnson

2Q Revenues: $15.1 billion (+13%)

2Q Earnings: $3.1 billion (+9%)

YTD Revenues: $30.2 billion (+15%)

YTD Earnings: $5.7 billion (-8%)

Comments: Worldwide Pharmaceutical sales were $6.1 billion in the quarter, up 5.8%. Topamax, Remicade, Risperdal, Risperdal Consta, Invega and Concerta contributed to this growth. In the quarter, the European Commission granted marketing authorization for Invega for the treatment of schizophrenia and the FDA approved an additional indication for Invega for long-term maintenance of schizophrenia. Worldwide consumer segment sales were $3.6 billion in the quarter, up 48.6%. YTD earnings reflect an IPR&D of $807 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters